JP2012082234A5 - - Google Patents

Download PDF

Info

Publication number
JP2012082234A5
JP2012082234A5 JP2012015831A JP2012015831A JP2012082234A5 JP 2012082234 A5 JP2012082234 A5 JP 2012082234A5 JP 2012015831 A JP2012015831 A JP 2012015831A JP 2012015831 A JP2012015831 A JP 2012015831A JP 2012082234 A5 JP2012082234 A5 JP 2012082234A5
Authority
JP
Japan
Prior art keywords
compound
cancer
composition
inhibiting
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012015831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012082234A (ja
JP5520325B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012082234A publication Critical patent/JP2012082234A/ja
Publication of JP2012082234A5 publication Critical patent/JP2012082234A5/ja
Application granted granted Critical
Publication of JP5520325B2 publication Critical patent/JP5520325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012015831A 2005-10-06 2012-01-27 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 Active JP5520325B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72415805P 2005-10-06 2005-10-06
US60/724,158 2005-10-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008534673A Division JP5152922B2 (ja) 2005-10-06 2006-10-04 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014002164A Division JP2014062129A (ja) 2005-10-06 2014-01-09 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法

Publications (3)

Publication Number Publication Date
JP2012082234A JP2012082234A (ja) 2012-04-26
JP2012082234A5 true JP2012082234A5 (enExample) 2012-08-16
JP5520325B2 JP5520325B2 (ja) 2014-06-11

Family

ID=37943366

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008534673A Active JP5152922B2 (ja) 2005-10-06 2006-10-04 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
JP2012015831A Active JP5520325B2 (ja) 2005-10-06 2012-01-27 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
JP2014002164A Pending JP2014062129A (ja) 2005-10-06 2014-01-09 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008534673A Active JP5152922B2 (ja) 2005-10-06 2006-10-04 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014002164A Pending JP2014062129A (ja) 2005-10-06 2014-01-09 プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法

Country Status (11)

Country Link
US (2) US20070082900A1 (enExample)
EP (1) EP1942900B1 (enExample)
JP (3) JP5152922B2 (enExample)
CN (1) CN101360499B (enExample)
BR (1) BRPI0616985B1 (enExample)
CA (1) CA2627623C (enExample)
NO (1) NO20082093L (enExample)
NZ (1) NZ567151A (enExample)
TW (1) TWI421078B (enExample)
WO (1) WO2007044441A2 (enExample)
ZA (1) ZA200802998B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
JP2009529054A (ja) * 2006-03-08 2009-08-13 ノバルティス アクチエンゲゼルシャフト 神経障害の処置におけるピラゾロ［１，５ａ］ピリミジン−７−イルアミン誘導体の使用
WO2007139732A1 (en) * 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors
US20100143332A1 (en) * 2006-11-17 2010-06-10 Schering Corporation Combination therapy for proliferative disorders
AU2008251921A1 (en) 2007-05-08 2008-11-20 Merck Sharp & Dohme Corp. Methods of treatment using intravenous formulations comprising temozolomide
MX2009013336A (es) * 2007-06-07 2010-01-20 Schering Corp Sintesis de 3-aminopirazoles sustituidos.
AR069198A1 (es) * 2007-11-07 2010-01-06 Schering Corp Derivados de ribosil pirimidinas moduladores de quinasas de control chk1,y composiciones farmaceuticas que los comprenden utiles en el tratamiento del cancer.
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) * 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
WO2009126584A1 (en) * 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
MX2011004204A (es) * 2008-10-22 2011-08-12 Array Biopharma Inc Compuestos pirazolo [1,5-a] pirimidina sustituida como inhibidores de cinasa trk.
AU2009308675A1 (en) * 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
MA33032B1 (fr) * 2009-02-13 2012-02-01 Bayer Schering Pharma Ag Pyrimidines condensees
WO2010118207A1 (en) * 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
WO2011031979A1 (en) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Pharmaceutically useful heterocycle-substituted lactams
NZ601325A (en) 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
WO2011090935A1 (en) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN102971322B (zh) 2010-05-20 2016-02-17 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
NZ707432A (en) * 2012-11-16 2020-01-31 Univ Health Network Pyrazolopyrimidine compounds
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2014372638A1 (en) 2013-12-23 2016-06-16 Norgine B.V. Compounds useful as CCR9 modulators
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3439662T3 (da) 2016-04-04 2024-09-02 Loxo Oncology Inc Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AR110252A1 (es) * 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN111194317A (zh) * 2017-07-28 2020-05-22 林伯士拉克许米公司 Tyk2抑制剂与其用途
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
BR112021008176A2 (pt) 2018-10-30 2021-08-03 Kronos Bio, Inc. compostos, composições, e métodos para a modulação da atividade da cdk9.
EP3891152A4 (en) * 2018-12-07 2022-09-07 Betta Pharmaceuticals Co., Ltd TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS RELATED
EP3946350A4 (en) 2019-03-26 2022-09-07 Ventyx Biosciences, Inc. TYK2 PSEUDOKINASE LIGANDS
CA3160637A1 (en) 2019-11-08 2021-05-14 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
CN114728167B (zh) 2019-11-25 2024-03-19 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0438730Y2 (enExample) * 1986-03-26 1992-09-10
JP3039751U (ja) * 1996-12-09 1997-07-31 尚子 小園 鞄類用補助具
JP2002295682A (ja) * 2001-03-28 2002-10-09 Yazaki Corp 防水構造およびこの防水構造に用いられる座金部材
MXPA04012245A (es) * 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
DK1537116T3 (da) * 2002-09-04 2010-09-27 Schering Corp Pyrazolopyrimidiner egnede til behandling af cancersygdomme
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539162A (en) * 2002-09-04 2006-07-28 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7557110B2 (en) * 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP3940700B2 (ja) * 2003-05-22 2007-07-04 茂 相馬 楽器用ケース
AR049769A1 (es) * 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
JP3104094U (ja) * 2004-03-18 2004-09-02 チャン ホアン−リン 両用スーツケース
ATE533770T1 (de) * 2005-10-06 2011-12-15 Schering Corp Pyrazolopyrimidine als proteinkinaseinhibitoren
AR055206A1 (es) * 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
JP3174645U (ja) * 2012-01-19 2012-03-29 株式会社セイバン ランドセル

Similar Documents

Publication Publication Date Title
JP2012082234A5 (enExample)
JP2018516917A5 (enExample)
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2022017295A5 (enExample)
JP2015533176A5 (enExample)
JP2015534578A5 (enExample)
JP2014518544A5 (enExample)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP5785157B2 (ja) Ｐｌｋ１阻害剤および抗腫瘍剤を含む治療組合せ
TR201800962T4 (en) CDC7 KINAZI INHIBITORS AND THEIR USAGE
NZ597252A (en) Compounds for inhibiting mitotic progression
HRP20171727T1 (hr) Novi terapeutici
JP2016536286A5 (enExample)
JP2015193630A5 (enExample)
JP2014512356A5 (enExample)
JP2016522202A5 (enExample)
JP2013504582A5 (enExample)
JP2018534289A5 (enExample)
JP2018525358A5 (enExample)
JP2016504325A5 (enExample)
JP2009506054A5 (enExample)
JP2019506392A5 (enExample)
JP2013544892A5 (enExample)
JP2014530181A5 (enExample)
JP2015518053A5 (enExample)